Coartem Baby: A Game-Changer for Malaria Treatment in Infants
The approval of Coartem Baby by Swiss regulators marks a breakthrough in malaria treatment for infants. This drug, tailored for babies weighing 2-5 kg, could significantly reduce malaria-related deaths among children in Africa, where the disease claims many young lives due to inadequate early diagnosis and treatment.
- Country:
- Uganda
The approval of Coartem Baby by Swiss medical regulators has ushered in a new era of hope in the fight against malaria in infants. This sweet-tasting tablet designed specifically for babies weighing between 2 and 5 kilograms addresses a significant gap in malaria treatment.
Before Coartem Baby, health professionals had to painstakingly adjust dosages intended for older children to fit infants, often running the risk of overdose or toxicity. With Coartem Baby on the horizon, Ugandan authorities are poised to update clinical guidelines to expedite its rollout.
This development is crucial in Africa, which accounts for 95% of global malaria deaths, affecting primarily young children. The Malaria Consortium lauded the drug's approval as a 'major leap forward' in saving lives in malaria-affected regions.
(With inputs from agencies.)
Google News